000 01007 a2200289 4500
005 20250515191827.0
264 0 _c20091130
008 200911s 0 0 eng d
022 _a1527-3792
024 7 _a10.1016/j.juro.2009.08.193
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSinger, Frederick R
245 0 0 _aEditorial comment.
_h[electronic resource]
260 _bThe Journal of urology
_cDec 2009
300 _a2676; dscussion 2676 p.
_bdigital
500 _aPublication Type: Comment; Journal Article
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aDenosumab
650 0 4 _aFractures, Bone
_xetiology
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aProstatic Neoplasms
_xtherapy
650 0 4 _aRANK Ligand
_xtherapeutic use
773 0 _tThe Journal of urology
_gvol. 182
_gno. 6
_gp. 2676; dscussion 2676
856 4 0 _uhttps://doi.org/10.1016/j.juro.2009.08.193
_zAvailable from publisher's website
999 _c19228764
_d19228764